NSCLC综合基因组图谱揭示EGFR外显子20插入的多样性与共存分子改变
该研究对14,483例NSCLC标本行杂交捕获综合基因组图谱(CGP)检测。TP53(56%)等为常见共存改变,肿瘤突变负荷低,5例接受一/二代EGFR-TKI者均无应答。
要点
- EGFRex20ins占NSCLC的1.8%、占EGFR突变者的12%,类型高度多样。
- 最常见类型为D770_N771>ASVDN(21%)与N771_P772>SVDNP(20%)。
- 共存改变以TP53(56%)为主,肿瘤突变负荷低,5例一/二代TKI均无应答。
核心结论
- EGFRex20ins在EGFR突变NSCLC中占12%,类型多样且对一/二代EGFR-TKI无应答,是值得重点干预的人群。
研究设计与样本
- 对14,483例临床注释的连续NSCLC标本前瞻性行杂交捕获CGP,平均覆盖深度>650X,检测236或315个癌症相关基因。
主要发现
- 263例(1.8%)检出EGFRex20ins,占EGFR突变病例的12%(263/2251)。
- EGFR扩增见于22%(57/263);共存改变常见TP53(56%)、CDKN2A(22%)、CDKN2B(16%)、NKX2-1(14%)、RB1(11%),其他已知肺癌驱动基因共存改变少见(5%)。
- 平均肿瘤突变负荷低(均值4.3,范围0至40.3 mutations/Mb)。
- 5例患者的一/二代EGFR-TKI临床结局可获取,均无应答。
临床怎么用
- 对NSCLC行CGP可识别EGFRex20ins及其共存改变,提示该类患者不宜依赖一/二代EGFR-TKI,应关注新型EGFR-TKI的临床研究。
局限性
- EGFR-TKI疗效数据仅来自5例患者,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: EGFR exon 20 insertions (EGFRex20ins) comprise an uncommon subset of EGFR-activating alterations relatively insensitive to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). However, recent early clinical data suggests these patients may benefit from newer-generation EGFR-TKIs. Comprehensive genomic profiling (CGP) identifies a broad spectrum of EGFRex20ins and associated co-occurring genomic alterations (GAs) present in NSCLC. METHODS: Hybrid capture-based CGP was performed prospectively on 14,483 clinically annotated consecutive NSCLC specimens to a mean coverage depth of greater than 650X for 236 or 315 cancer-related genes. RESULTS: Of 14,483 NSCLC cases, CGP identified 263 (1.8%) cases with EGFRex20ins, representing 12% (263 of 2251) of cases with EGFR mutations. Sixty-four unique EGFRex20ins were identified, most commonly D770_N771>ASVDN (21%) and N771_P772>SVDNP (20%). EGFR amplification occurred in 22% (57 of 263). The most common co-occurring GAs effected tumor protein p53 (TP53) (56%), cyclin dependent kinase inhibitor 2A (CDKN2A) (22%), cyclin dependent kinase inhibitor 2B (CDKN2B) (16%), NK2 homeobox 1 (NKX2-1) (14%) and RB transcriptional corepressor 1 (RB1) (11%); co-occurring GAs in other known lung cancer drivers were rare (5%). Average tumor mutational burden was low (mean 4.3, range 0 to 40.3 mutations/Mb). Clinical outcomes to first- and second-generation EGFR TKIs were obtained for five patients and none responded. CONCLUSIONS: In the largest series of EGFRex20ins NSCLC, diverse EGFRex20ins were detected in 12% of EGFR-mutant NSCLC, a higher frequency than previously reported in smaller single-institution studies. Clinical outcomes showed lack of response to EGFR TKIs. Tumor mutational burden was low, consistent with non-smoking associated NSCLC. Comprehensive sequencing revealed increased proportion and wide variety of EGFRex20ins, representing a population of patients significant enough for focused efforts on effective interventions.
引用
- Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. J Thorac Oncol. 2018. PMID: 29981927. doi:10.1016/j.jtho.2018.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。